Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Skin Basal Cell Carcinoma Clinical Trial

Official title: A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients

Status Completed

Clinical Trial Summary

This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Overall response rate of basal cell carcinoma (BCC) in subjects at 6 weeks.

SECONDARY OBJECTIVES:

I. Suppression of GLI1 (glioma-associated oncogene) expression in treated BCCs as compared with baseline.

II. Safety assessment of Remetinostat after 6 weeks of topical treatment.

OUTLINE:

Tumors receive Remetinostat topically three times per day (TID) for 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for at least 4 weeks. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Basal Cell
• Skin Basal Cell Carcinoma

• NCT number: NCT03180528
• Study type: Interventional
• Source: Stanford University
• Status: Completed
• Phase: Phase 2
• Start date: July 7, 2018
• Completion date: December 31, 2020